MJN Neuroserveis
Wearable technology to predict epileptic seizures.
- B2C
- manufacturing
- marketplace & ecommerce
- subscription
- health
- medical devices
- biotechnology
- hardware
- big data
- deep tech
- machine learning
- nanotech
- computer vision
- connected device
- mobile app
- iot internetofthings
- artificial intelligence
- biotechnology
- horizon europe
- sustainable development goals
- dt and ls
- core ai
- ai applications
- eit ecosystem
- predictive analytics
- wearable
- neurology
- eit health
- digital care
- patient care
- direct-to-consumer
- eit kic partners
- medical diagnostics
- ai model layer
- health information
- bridgehead europe (eit health)
- epilepsy
- bridgehead europe 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€1.0k | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 28 % | (89 %) | 2732 % | 226 % | 360 % | 60 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (412 %) | (394 %) | (6178 %) | (83 %) | 40 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (309 %) | (329 %) | (2762 %) | (83 %) | (26 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
MJN Neuroserveis, accessible via mjn.cat, is a pioneering startup in the healthcare technology sector. The company specializes in developing innovative solutions for neurological disorders, with a particular focus on epilepsy. Their flagship product, MJN-SERAS, is a wearable device designed to predict epileptic seizures, providing real-time alerts to patients and caregivers. This technology aims to significantly improve the quality of life for individuals suffering from epilepsy by offering them greater independence and safety.
MJN Neuroserveis primarily serves patients with epilepsy, their families, and healthcare providers. The company operates in the global healthcare market, targeting regions with high incidences of epilepsy and a strong demand for advanced medical technologies. By addressing a critical need in the healthcare system, MJN Neuroserveis positions itself as a vital player in the medical device industry.
The business model of MJN Neuroserveis revolves around the sale and subscription of their wearable device and associated software services. They generate revenue through direct sales of the MJN-SERAS device, as well as through subscription fees for continuous monitoring and data analysis services. This dual revenue stream ensures a steady income while fostering long-term relationships with their clients.
In summary, MJN Neuroserveis is a forward-thinking company dedicated to enhancing the lives of epilepsy patients through cutting-edge technology. Their innovative approach and commitment to improving patient outcomes make them a standout in the healthcare technology market.
Keywords: healthcare, technology, epilepsy, wearable device, seizure prediction, patient safety, medical device, global market, subscription model, innovation.